Monopar Therapeutics (MNPR) Retained Earnings (2016 - 2026)

Monopar Therapeutics has reported Retained Earnings for 10 years, with the latest figure at -$89.5 million in Q4 2025.

• Quarterly Retained Earnings fell 248766.37% year-over-year to -$89.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$89.5 million (down 248766.37% YoY) and the FY2025 annual result came in at -$89.5 million, down 248766.37% from the prior year.
• Retained Earnings declined to -$89.5 million in Q4 2025 per MNPR's latest filing, from -$84.3 million in the prior quarter.
• Over five years, Retained Earnings peaked at $60.7 million in Q1 2022 and troughed at -$89.5 million in Q4 2025.
• A 5-year average of -$28.0 million and a median of -$18.1 million in 2021 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 1190591.06% in 2022, down 1639267.75% in 2022.
• Over 5 years, Retained Earnings stood at -$3160.0 in 2021, then tumbled by 1639267.75% to -$51.8 million in 2022, then jumped by 99.97% to -$14132.0 in 2023, then soared by 354.68% to $35992.0 in 2024, then slumped by 248766.37% to -$89.5 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$89.5 million, -$84.3 million, and $77577.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.